Profil Institute Presents at the American Diabetes Association’s 75th Annual Scientific Sessions in Boston

Profil Institute Presents at the American Diabetes Association’s 75th Annual Scientific Sessions in Boston

SAN DIEGO, May 29, 2015 – Profil Institute for Clinical Research, an clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, will present study results at next week’s American Diabetes Association (ADA) 75th Scientific Sessions, June 5 – 9 in Boston, Massachusetts.

Poster and oral presentations co-authored by Profil Institute scientists include:

 

Unique Profile of the Weekly Insulin Hm12470: Very Slow Onset of Action, Rapid Off-Rate Similar to Insulin, and Absence of Insulin Receptor Downregulation (96-OR)

Once-Weekly Combination of GLP-1R Agonist and Insulin (HM14220) Offers Improved Glycemic Control and Reduced Weight Gain Risk (172-OR)

LAPS GLP/GCG Dual Agonist, HM12525A, Confirmed Prolonged Pharmacokinetics in Healthy Volunteers: A First-in-Human Phase 1 Study (173-OR)

Dose-Response Improvements in Glycemic Control and Body Weight Reductions with HM11260C, a Once-Weekly GLP-1 Receptor Agonist with Liraglutide as Reference, in Type 2 Diabetes (T2DM) (278-OR)

Postmeal Glycemia following U-400 Ultra-Rapid-Acting/Basal Insulin BIOD-531 vs. Premixed and U-500 Insulins in Patients with Type 2 Diabetes (977-P)

A Single Dose Euglycemic Clamp Study in Healthy Subjects Demonstrating Pharmacokinetic and Pharmacodynamic Equivalence between MK-1293 and Lantus (1026-P)

Superagonistic Mechanism of Increased Glucodynamic and Weight Loss Effects of LAPSCA-Exendin-4 (HM11260C) (1116-P)

Potent Weight Loss Mechanism of the Novel Long-Acting GLP-1/Glucagon Dual Receptor Agonist (HM12525A) (1118-P)

LAPS-Exendin-4 (HM11260C) Significantly Enhances Insulin Secretion and ß-Cell Responsiveness in Subjects with Type 2 Diabetes Mellitus (T2DM) (1123-P)

Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling Predict Similar Dosing Frequencies for U-400 Ultra-Rapid-Acting Insulin BIOD-531 vs. Marketed Prandial-Basal Insulins (2531-PO)

Noninferior Delay in Gastric Emptying vs. Liraglutide and Favorable Glucometabolic Profile following Treatment with LAPSExendin-4 (HM11260C) in Subjects with Type 2 Diabetes Mellitus (T2DM) (2561-PO)

Once-a-Month Treatment with HM11260C Improves Glycemic Control in Type 2 Diabetes (T2DM)—Interim Data from a 16-Week Study (105-LB)

Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of BIOD-961 Compared with Marketed Glucagons (2-LB)

Ultra-Rapid-Acting/Basal Concentrated Insulin BIOD-531 Demonstrates Superior Postprandial Glucose Control and Potential for Flexible Post-meal Dosing Compared with Marketed Prandial/Basal Insulins in Insulin-Resistant Patients with Type 2 Diabetes (92-LB )

Significant Effects of HM11260C on Body Weight over 20 Weeks in Obese Subjects without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study (303-LB)

Moderator (3CT-PT09)
Development in Basal Insulin, Guided Audio Poster Tour, Moderator: Dr. Marcus Hompesch, CEO and President, Profil Institute for Clinical Research, Inc

About Profil Institute for Clinical Research, Inc.
Profil Institute is an early engagement clinical research organization (CRO) exclusively focused on metabolic diseases, including diabetes, obesity and NAFLD/NASH. The company is recognized globally for its scientific expertise, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes. Profil Institute provides a full scope of CRO services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.

Profil Institute’s expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices. The company’s clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia.

Profil Institute is also widely recognized as an innovator of methodologies, including its Automated Glucose Clamp technology, and for driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners. For more information, visit www.profilinstitute.com.

For further information, please contact:
Abby Devine
Profil Institute for Clinical Research, Inc.
Corporate Communications
abby.devine@profilinstitute.com
+1 (858) 663-6148